1. anti-arrhythmatic agents - drugs

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/19

encourage image

There's no tags or description

Looks like no tags are added yet.

20 Terms

1
New cards

Quinidine (Quinidex)

class 1A: Na+ channel blocker (non-pacemaker)

moderate decrease in slope of phase 0 & AP peak

increase APD

  • also blocks K+ channels (also inhibits phase 3)

  • pro-arrhythmic & anticholinergic effect

  • QT prolongation (prolong AP duration)

MOA: inhibit K+ channels

metabolism: substrate of CYP3A4 & inhibitor of CYP2D6

Adverse Effects:

  • cinchonism (blurred vision, tinnitus, headache, disorientation, psychosis)

  • thrombocytopenia (low platelets)


2
New cards

Procainamide (Procan)

class 1A: Na+ channel blocker (non-pacemaker)

moderate decrease of slope of phase 0 & AP peak

increase APD

  • also blocks K+ channels (also inhibits phase 3)

  • pro-arrhythmic & anticholinergic effect

  • QT prolongation (prolong AP duration)

MOA: inhibit K+ channels

metabolism: acetylated in liver to N-acetyl procainamide (NAPA) → prolongs AP duration

adverse effects: systemic lupus erythromatosis (SLE)

3
New cards

Disopyramide (Norpace)

class 1A: Na+ channel blocker (non-pacemaker)

moderate decrease in slope of phase 0 & AP peak

increase APD

  • also blocks K+ channels (also inhibits phase 3)

  • pro-arrhythmic & MOST anticholinergic effect out of class 1A

  • QT prolongation (prolongs AP duration)

MOA: inhibit K+ channels

metabolism: first pass so only given IV

adverse effects: negative inotropic effect (may precipitate heart failure)

contraindications: elderly, glaucoma, heart failure

4
New cards

Lidocaine (Xylocaine)

class 1B: Na+ channel blocker (non-pacemaker)

weak decrease in slope of phase 0 & AP peak

slight decrease APD

  • high safety profile

  • least cardiotoxic agent among Na+ channel blockers

MOA: shorten phase 3 repolarization & AP duration

adverse effects:

  • nystagmus (CNS effects)

  • drowsiness, slurred speech, paresthesia, agitation, confusion, convulsions


5
New cards

Mexiletine (Mexitil)

class 1B: Na+ channel blocker (non-pacemaker)

weak decrease in slope of phase 0 & AP peak

slight decrease APD

  • oral from of lidocaine

MOA: shorten phase 3 repolarization & AP duration

adverse effects: nausea, vomiting, dyspepsia


6
New cards

Flecainide (Tambocor)

class 1C: Na+ channel blocker (non-pacemaker)

strong decrease in slope of phase 0 & AP peak

NO APD effect

MOA: dissociate slowly & minor effect on AP duration

metabolism: CYP2D6 substrate

adverse effects: blurred vision, dizziness, nausea


7
New cards

Propafenone (Rythmol)

class 1C: Na+ channel blocker (non-pacemaker)

strong decrease in slope of phase 0 & AP peak

NO APD effect

  • beta-blocking effects

MOA: dissociates slowly & minor effect on AP duration

metabolism: CYP2D6 substrate

adverse effects:

  • bronchospasm

  • blurred vision, dizziness, nausea

contraindications: asthma


8
New cards

Atenolol (Tenormin)

class 2: beta1 blocker (pacemaker)

  • decreased slope of phase 4 depolarization & prolonged repolarization at AV node

  • delay phase 4

  • block sympathetic activity

  • block beta-adrenergic receptors & antagonize increased sympathetic tones & high levels of NE & E

  • decrease HR (SA) & AV nodal conduction

  • beta1 selective → eliminate side effects related to lungs (cardioselective)

safe for asthma

contraindications: asthma, AV block, congestive heart failure, diabetes mellitus


9
New cards

Bisoprolol (Zebeta)

class 2: beta1 blocker (pacemaker)

  • decreased slope of phase 4 depolarization & prolonged repolarization at AV node

  • delay phase 4

  • block sympathetic activity

  • block beta-adrenergic receptors & antagonize increased sympathetic tones & high levels of NE & E

  • decrease HR (SA) & AV nodal conduction

  • beta1 selective → eliminate side effects related to lungs (cardioselective)

beta1 selective at low dose

contraindications: asthma, AV block, congestive heart failure, diabetes mellitus


10
New cards

Metoprolol (Lopressor)

class 2: beta1 blocker (pacemaker)

  • decreased slope of phase 4 depolarization & prolonged repolarization at AV node

  • delay phase 4

  • block sympathetic activity

  • block beta-adrenergic receptors & antagonize increased sympathetic tones & high levels of NE & E

  • decrease HR (SA) & AV nodal conduction

  • beta1 selective → eliminate side effects related to lungs (cardioselective)

safe for asthma

contraindications: asthma, AV block, congestive heart failure, diabetes mellitus


11
New cards

Esmolol (Brevibloc)

class 2: beta1 blocker (pacemaker)

  • decreased slope of phase 4 depolarization & prolonged repolarization at AV node

  • delay phase 4

  • block sympathetic activity

  • block beta-adrenergic receptors & antagonize increased sympathetic tones & high levels of NE & E

  • decrease HR (SA) & AV nodal conduction

  • beta1 selective → eliminate side effects related to lungs (cardioselective)

safe for asthma

shortest acting

contraindications: asthma, AV block, congestive heart failure, diabetes mellitus

12
New cards

Amiodarone (Cordarone)

class 3: K+ channel blockers (non-pacemaker)

  • delays repolarization (phase 3)

  • diminish outward potassium current during repolarization phase

  • prolonged AP duration without altering phase 0

  • can induce arrhythmias

drug notes:

  • iodine moiety in structure → cause thyroid dysfunction

  • inhibits lots of substrates (CYP1A2, CYP2A4, CYP2C9, CYP2D6)

    • lots of drug interactions

  • induce QR prolongation w/ class 1 Quinidine

  • precipitate bradycardia & cardiac arrest w/ beta blockers & calcium channel blockers

metabolism: 6 Ps of amiodarone

  1. prolongs AP duration

  2. photosensitivity

  3. pigmentation of skin (blue)

  4. peripheral neuropathy

  5. pulmonary alveolitis & fibrosis

  6. peripheral conversion of T4 to T3 inhibited

adverse effects:

long term

  • thyroid dysfunction (hypo OR hyperthyroidism)

  • pulmonary fibrosis

  • ocular toxicity (red-green halos, blurred vision, blindness)

  • optic neuritis & corneal deposits

  • peripheral neuropathy

  • hepatic toxicity

  • dermatologic effects - blue/gray skin

short term

  • more arrhythmia (bradycardia)

  • hypotension

  • nausea

  • vein irritant/phlebitis

  • photosensitivity

never give >6 months


13
New cards

Dronedarone (Multaq)

class 3: K+ channel blocker (non-pacemaker)

  • delays repolarization (phase 3)

  • diminish outward potassium current during repolarization phase

  • prolonged AP duration without altering phase 0

  • can induce arrhythmias

drug notes:

  • not as effective as Amiodarone (less drug interactions, less side effects, less lipophilic)

    • inhibits CYP3A4, CYP2D6

  • lower tissue accumulation than Amiodarone

  • shorter serum half life than Amiodarone

    • t1/2 = 4-7 days

  • affected by CYP3A4 inhibitors/inducers

metabolism: first pass effect

adverse effects: liver injury, QT prolongation


14
New cards

Sotalol (Betapace)

class 3: K+ channel inhibitor (non-pacemaker)

  • delays repolarization (phase 3)

  • diminish outward potassium current during repolarization phase

  • prolonged AP duration without altering phase 0

  • can induce arrhythmias

drug notes:

  • adverse effects associated with beta-blockers

metabolism:

  • NOT metabolized

  • unchanged in excretion by kidneys

adverse effects:

  • life threatening arrhythmia

  • QT prolongation

  • same as beta-blocker adverse effects:

    • AV conduction block

    • bradycardia

    • cardiac arrest

    • hypotension


15
New cards

Dofetilide (Tikosyn)

class 3: K+ channel inhibitor (non-pacemaker)

  • delays repolarization (phase 3)

  • diminish outward potassium current during repolarization phase

  • prolonged AP duration without altering phase 0

  • can induce arrhythmias

metabolism: unchanged excretion by kidneys

adverse effects: pro arrhythmia, serous arrhythmia (torsade de pointe)


16
New cards

Ibutilide (Corvert)

class 3: K+ channel inhibitor (non-pacemaker)

  • delays repolarization (phase 3)

  • diminish outward potassium current during repolarization phase

  • prolonged AP duration without altering phase 0

  • can induce arrhythmias

metabolism:

  • first pass metabolism

  • NOT oral

adverse effects: high risk of QT prolongation, pro arrhythmic


17
New cards

Diltiazem (Cardizem) & Verapamil (Calan)

class 4: non-DHP Ca2+ channel blocker (pacemaker)

  • block L-type calcium channels in firing cells

  • decrease HR (SA) & AV nodal conduction

  • slow down depolarization rate of phase 1 & phase 4

  • reduce automaticity in SA node

  • reduce AV conduction

drug notes:

  • used for anti-arrhythmic control

  • substrates & inhibitors of CYP3A4

  • drug-drug interactions

    • beta blockers

    • statins (simvastatin)

    • grapefruit juice may increase plasma levels of verapamil (bc inhibits metabolism so drug overdose)

adverse effects: hypotension, heart block, worsening heart failure


18
New cards

Adenosine (Adenocard)

  • has ACh-like effect on heart with greatest inhibition on AV node

  • IV only by rapid bolus infusion

    • super fast onset & super short duration

    • t1/2 = 8 secs

  • drug interactions: caffeine & theophylline antagonize adenosine in lungs

MOA: activates adenosine A1 receptors in heart → increase in ACh to slow HR

adverse effects: bronchospasm

use w caution in asthmatics


19
New cards

Digoxin (Lanoxin)

  • stimulates parasympathetic → slow HR

  • clinical use: when digoxin slows AV nodal conduction it controls the ventricular response in atrial fibrillation

MOA: anti-arrhythmic effects similar to Adenosine (ACh-like effect to slow HR & AV nodal conduction)

adverse effects:

  • ventricular tachycardia (esp w diuretics & hypokalemia)

  • AV depression

  • AV block

  • toxic levels can cause GI upset, altered cognition, or blurred/yellow vision

    • ANTIDOTE: Digibind


20
New cards

Magnesium

  • blocked Ca2+ mediated arrhythmias

  • give 1-2 grams IV to prevent recurrent Torsades de Pointes

  • can treat arrhythmias caused by digoxin intoxication

  • anti-arrhythmic effect from IV, NOT oral

MOA: Ca2+ antagonist